NuCana is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by applying its ProTide™ technology to transform some of the prescribed chemotherapy agents, nucleoside analogs, into medicines. Utilizing its proprietary technology, Co. is developing new medicines, ProTides, designed to overcome main cancer resistance mechanisms and generate concentrations of anti-cancer metabolites in cancer cells. Co.'s ProTide candidates, Acelarin® and NUC-3373, are chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two chemotherapy agents. Co. is evaluating NUC-7738 in clinical trial for patients with solid tumors. We show 1 historical shares outstanding datapoints in our NCNA shares outstanding history coverage, used to compute NCNA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NCNA market cap history over the course of time is important for investors
interested in comparing NCNA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NCNA versus a peer is one thing; comparing
NCNA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NCNA can fluctuate over the course of history.
With this page we aim to empower investors researching NCNA by allowing them to research the NCNA market cap history. |
Free NCNA Email Alerts:
Video: The Importance of Market Cap
